With uncertainty surrounding the future of government funding, the onus is being placed on the private sector to continue driving new discoveries.
Michael Miller, PhD
Advertisement
Articles by Michael Miller, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
3
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
4
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences
5